Calcitonin News and Research

RSS

Calcitonin is a 32-amino acid linear polypeptide hormone that is produced in humans primarily by the parafollicular cells (also known as C-cells) of the thyroid, and in many other animals in the ultimobranchial body.

Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

Dermatology researcher Nicole Ward, PhD, has earned her third National Institutes of Health grant in a year - including two that scored in the first percentile. With this most recent award, an R21, she will investigate the role the nervous system plays in psoriasis - an inflammatory autoimmune disease characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin.

17 Aug 2013

GSD receives FDA Clearance for 25-OH Vitamin D Total ELISA test

Gold Standard Diagnostics, Corp., a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, announced 510k FDA Clearance of its 25-OH Vitamin D, Total ELISA.

24 Jul 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.

28 Mar 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

AstraZeneca receives FDA approval for Cometriq to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).

29 Nov 2012

Calcium-related hormone could help identify pneumonia

Serum procalcitonin measurements could improve the accuracy of pneumonia diagnoses when chest radiographs give indeterminate results, indicate US study findings.

12 Nov 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Unigene first quarter net loss decreases to $6.0 million

Unigene Laboratories, Inc., today announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis

Tarsa Therapeutics today presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA-, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

Unigene second quarter revenue decreases to $2.5 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.

8 Aug 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

Magnesium essential for absorption and metabolism of vitamin D and calcium

Magnesium deficiency is an important factor in the results obtained from vitamin D. According to Dr. Carolyn Dean, MD, ND, magnesium expert and Medical Director of the nonprofit Nutritional Magnesium Association, the effectiveness and benefits of vitamin D are greatly undermined in the absence of adequate levels of magnesium in the body.

15 Jun 2011

Skin cell-derived CGRP-beta may cause chronic pain

A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.

9 Jun 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

18 May 2011